A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.

Trial ID # NCT04570839
Phase I/II
Drug Class Immunotherapy: Checkpoint Inhibitors/PVRIG
Drug Name COM701
Drugs in Trial BMS-986207, COM701, Nivolumab
Eligible Participant

Platinum resistant ovarian cancer

Patients Enrolled

20; median 4 prior therapies (1-10)

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, DCR, evaluated per RECIST


ORR: 20% (4PR - 3 HGSOC, 1 OCCC)
DCR: 45% (4PR, 5SD)

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE: overall (35%)


The combination of COM701 + BMS-986207 + nivolumab is well tolerated and has encouraging durable anti-tumor activity with immune activation in patients with platinum resistant HGSOC and OCCC


Gaillard S et al. Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer. J Immunother Cancer (2023) 11: abstract 669

Gaillard S et al. Poster

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.